Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

The harms of screening: new attention to an old concern.

Woolf SH, Harris R.

JAMA. 2012 Feb 8;307(6):565-6. doi: 10.1001/jama.2012.100. No abstract available.

PMID:
22318274
2.

[Decision of the Federal Joint Committee on screening for chorionicity - benefit assessment in the absence of screening studies].

Schwalm A, Bertelsmann H, Gruber S, Wietschel G, Matthias K.

Gesundheitswesen. 2013 Jan;75(1):13-21. doi: 10.1055/s-0032-1311615. Epub 2012 Jul 30. German.

PMID:
22847814
3.

Appropriate use of screening and diagnostic tests to foster high-value, cost-conscious care.

Qaseem A, Alguire P, Dallas P, Feinberg LE, Fitzgerald FT, Horwitch C, Humphrey L, LeBlond R, Moyer D, Wiese JG, Weinberger S.

Ann Intern Med. 2012 Jan 17;156(2):147-9. doi: 10.7326/0003-4819-156-2-201201170-00011.

PMID:
22250146
4.

Overview of screening: where we are and where we may be headed.

Harris R.

Epidemiol Rev. 2011;33:1-6. doi: 10.1093/epirev/mxr006. Epub 2011 Jun 27.

PMID:
21709142
5.

To screen-or not? Questions to put to your physician before having a test.

Hobson K.

US News World Rep. 2007 Apr 23;142(14):70, 73-4. No abstract available.

PMID:
17477332
6.
7.
8.

Cost-effectiveness decision making and US public opinion.

Botta MD, Blendon RJ, Benson JM.

JAMA Intern Med. 2014 Jan;174(1):141-3. doi: 10.1001/jamainternmed.2013.11332. No abstract available.

PMID:
24100698
9.

New proposals to improve US cancer care and control costs.

Furlow B.

Lancet Oncol. 2014 Aug;15(9):921-2. No abstract available.

PMID:
25225684
10.

Cost analysis of screening for, diagnosing, and staging prostate cancer based on a systematic review of published studies.

Ekwueme DU, Stroud LA, Chen Y.

Prev Chronic Dis. 2007 Oct;4(4):A100. Epub 2007 Sep 15. Review.

11.

The economics of prostate cancer screening.

Benoit RM, Naslund MJ.

Oncology (Williston Park). 1997 Oct;11(10):1533-43; discussion 1543, 1547-8. Review.

12.

Cost effectiveness in context.

Schechter CB.

J Clin Oncol. 2007 Feb 20;25(6):609-10. No abstract available.

PMID:
17308263
13.

Patient autonomy and clinician integrity in treatment decisions.

Jenkins I.

JAMA. 2011 May 11;305(18):1861; author reply 1861-2. doi: 10.1001/jama.2011.585. No abstract available.

PMID:
21558516
14.

FROM MEDICAL DECISION-MAKING TO MEDICAL-COST-COMPARATIVE DECISION-MAKING.

Fontenot SF.

Physician Leadersh J. 2015 Sep-Oct;2(5):54-6. No abstract available.

PMID:
26529879
15.

Physician stewardship of health care in an era of finite resources.

Reuben DB, Cassel CK.

JAMA. 2011 Jul 27;306(4):430-1. doi: 10.1001/jama.2011.999. No abstract available.

PMID:
21791692
16.

Screening and insurance.

Jha S.

J Am Coll Radiol. 2013 Dec;10(12):949-52. doi: 10.1016/j.jacr.2013.09.017.

PMID:
24295946
17.

American Cancer Society: Cost of screening mammography. Issues, recommendations, and solutions.

[No authors listed]

Cancer. 1987 Oct 1;60(7 Suppl):1694-9. No abstract available.

18.

Basic issues in population screening for cancer.

Cole P, Morrison AS.

J Natl Cancer Inst. 1980 May;64(5):1263-72.

PMID:
6767876
19.

Medicare coverage for technological innovations.

Hart S.

N Engl J Med. 2004 Aug 12;351(7):719-20; author reply 719-20. No abstract available.

PMID:
15309749
20.

Does reimbursement affect physician decision making?

Bennett CL, Stinson TJ.

Cancer Treat Res. 2000;102:137-49. No abstract available.

PMID:
10650485

Supplemental Content

Support Center